Editorial Assistance Kristen Holt
Design and Production Amy Finkel
HIV and Hepatitis C Conference
Resistance Workshop - June 1999, San Diego
First Lipodystrophy Conference - June 1999, San Diego
ICAAC - September 1999, San Francisco
7th European Conference on
Clinical Aspects and Treatment of HIV,
October 1999, Lisbon
AASLD - American Association for the Study of Liver Disease, Dallas, November 1999
IDSA - November, 1999
We encourage you to read the articles on our website which contain more comprehensive treatment information. NATAP has an e-mail treatment news service. When there is breaking treatment news, NATAP will e-mail to you a report of this information. If you’d like to subscribe, free of charge, please send NATAP your e-mail address.
-.Table of Contents.-
from the Publisher
Correlating CD4 & Viral Load with risk for opportunistic infections; when and with what to begin therapy; resistance testing; new drugs (articles peppered throughout newsletter)
Switch to PI-sparing
Switching from PI to NVP Regimen in HIV+ subjects under long-term successful treatment; switch to NVP due to lipodystrophy; switch from PI-based regimen to Efavirenz regimen; switching Protease Inhibitor Abacavir: Preliminary 16-week data (Lisbon)
Sparing for Initial or First-line therapy
(also see Lisbon late breaker on NVP in high viral loads)
Atlantic Study; Efavirenz Studies; Abacavir; MKC-442; Three NRTIs as Initial Therapy: AZT+ddI+3TC; Pilot open-label study of 3TC+AZT+Abacavir+Efavirenz
«.PROTEASE INHIBITOR STUDIES.»
The information in this
newsletter is only for educational purposes.
Compassionate Access Programs
ABT-378: 1 888 711-7193
PMPA: 1 800 276-0231 (8am-6pm
compassionate access program for ABT-378 for individuals with limited options.
Larger traditional expanded access program expected to begin in early 2000. 888
711-7193. A small PMPA compassionate access program has started also for
individuals with limited options.
All rights reserved. Noncommercial reproduction is encouraged. Extended reproduction requires the permission of NATAP. All subscription lists are kept confidential.
NATAP has a unique mission. We are committed to providing the most comprehensive, accurate and real-time up-to-date treatment information available. Therefore we do not have a set publication schedule. When there are advances in AIDS treatment we will publish them either in this newsletter, on our web site or if they are urgent in a priority fax or e-mail notice.
A subscription to NATAP Reports will allow you to receive a copy of the newsletter as well as an entry on our e-mail list.
Please send us your e-mail
address. All our publications are free for those who cannot afford to pay;
however, we do
NATAP’s E-mail address is email@example.com
Phone: 212-219-0106 or 1-888-26-NATAP
580 Broadway, Ste 1010 NY, NY 10012